InvestorsHub Logo
Followers 19
Posts 1027
Boards Moderated 0
Alias Born 06/28/2013

Re: None

Monday, 12/16/2013 3:50:48 PM

Monday, December 16, 2013 3:50:48 PM

Post# of 1121
Heavy insider buying a couple of weeks ago. Perfect entry point post-offering.

Dr WASKAL (director of scientific affairs) likened CaPre's easy potential approval to "low hanging fruit"

Excellent results so far in P2, trial involving a couple hundred patients.
Also
This being a subsidiary of Neptune speaks volumes.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News